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Abstract The angiogenesis inhibitor endostatin is a fragment of
the NC1 domain of collagen XVIII. The generation of endostatin
has been investigated only in murine hemangioendothelioma cell
cultures and was ascribed to cathepsin L. Distinct endostatin-like
fragments were detected in human tissues and serum. To identify
proteinases able to generate such fragments, we incubated human
NC1 with proteinases of all classes, including cathepsin L. Eleven
out of 12 generate fragments with an N-terminus within the
same 15 residue stretch as those occurring physiologically,
indicating that this region is sensitive to many proteinases. None
correspond to mouse endostatin. However, the efficiencies of
these proteinases differed markedly. Some proteinases also
proved to degrade endostatin, pointing to another regulatory
loop of angiogenesis. ß 2000 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Angiogenesis is a process in which new blood vessels are
formed by sprouting from existing ones. It is required during
embryogenesis, tissue repair and tumor growth. A variety of
proteinases have been reported to promote angiogenesis, but
they have complex functions, which are far from being under-
stood [1^5]. The discovery of natural antiangiogenic factors
that correspond to fragments of larger proteins has led to the
realization that some proteinases can also cause inhibition of
angiogenesis. Examples of such fragments are angiostatin, a
proteolytic fragment of plasminogen [6] and endostatin, a
fragment of the carboxyl domain of collagen XVIII [7].
Both fragments have been shown to inhibit tumor growth
and metastasis. Endostatin-containing fragments circulate in
the plasma of apparently healthy people [8,9], suggesting that
the proteolytic release of endostatin from collagen XVIII is a
normal physiological process.
Collagen XVIII is the core protein of a heparan sulfate
proteoglycan of vascular and epithelial basement membrane
[10^15]. Its structure consists of a central region composed of
10 triple-helical domains, £anked by two non-triple-helical
domains: NC11 at the N-terminal and NC1 at the C-terminal
[11^15]. The structure of mouse NC1 consists of three re-
gions: (1) an N-terminal region comprising approximately
60 residues, responsible for the trimerization of collagen
XVIII polypeptides, (2) a central hinge region of approxi-
mately 70 residues and (3) a more compact 22 kDa C-termi-
nal, endostatin region with about 180 residues [8]. Endostatin
was originally detected in conditioned media of murine he-
mangioendothelioma (EOMA) cells as a fragment with the
N-terminal sequence HTHQD, able to inhibit endothelial
cell proliferation [7], migration [16,17], survival [18], as well
as angiogenesis and tumor growth [7]. A recent study [19]
showed that recombinant mouse NC1 itself does not inhibit
FGF-2-induced chorioallantoic membrane angiogenesis, while
endostatin does. This indicates that processing within the NC1
hinge region is needed to generate antiangiogenic e¡ects. In
mouse tissue and serum, endostatin-containing fragments of
collagen XVIII resulting from proteolytic cleavage upstream
in the hinge region have been detected ([8,20]; see also Fig. 2).
In human sera, similar endostatin-containing fragments are
present. There are indications that mouse endostatin-like pro-
tein fragments with extensions or deletions of a few residues at
the N-terminus or C-terminus of the 22 kDa fragment are
biologically active [17].
The proteinase that generates endostatin with the originally
described N-terminal sequence HTHQD in EOMA cell cul-
tures is cathepsin L [21], whereas metalloproteinases generate
a fragment 8 kDa larger than endostatin in a parallel process-
ing pathway [21]. Incubation of murine NC1 (mNC1) with
porcine pancreatic elastase also produced endostatin with
the N-terminal sequence HTHQD [22]. It is unlikely, however,
that cathepsin L and elastase are the universal proteinases
that generate endostatin or endostatin-like fragments from
collagen XVIII, when considering the variability in the N-
termini of endostatin-like fragments found in tissues, and
the fact that the amino acid sequence around the cathepsin
L/elastase cleavage site in mouse collagen XVIII is not well
conserved amongst species.
We therefore examined the processing of recombinant hu-
man NC1 (hNC1) with a number of di¡erent proteinases. Our
data show that cathepsins L, B and K, several matrix metal-
loproteinases (MMPs) and pancreatic elastase can generate
endostatin-like protein fragments, although with di¡erent ef-
¢ciencies. Moreover, our results demonstrate that some pro-
teinases, including cathepsins L, B, D and K degrade endo-
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statin or NC1 fragments very e⁄ciently, whereas others do
not.
2. Materials and methods
2.1. Proteinases
Mouse proMMP-9 was puri¢ed from culture media of transfected
baby hamster kidney cells, by using gelatin-Sepharose and concana-
valin A-Sepharose (Pharmacia) [23]. The catalytic domains of rabbit
MMP-12 and MMP-14 were puri¢ed from Escherichia coli (unpub-
lished). Recombinant proMMP-13 was provided by Dr. Lo¤pez-Ot|¤n
(Oviedo, Spain). Human proMMP-2 was from Boehringer Mann-
heim. ProMMPs were activated with 4-aminophenyl mercuric acetate.
Human cathepsins B and L and porcine pancreatic elastase were from
Calbiochem, and human cathepsin D from Sigma. Recombinant hu-
man procathepsin K was puri¢ed from Pichia pastoris [24], and acti-
vated by acidic pH.
The molar concentrations of active MMPs [25], cysteine proteinases
[26] and cathepsin D [27] were determined by titration with BB-94
(gift from Dr. van Wart, Roche), E64c (Sigma) and pepstatin A (Sig-
ma), respectively.
2.2. Processing of hNC1
Recombinant human N-£agged NC1 [17,21] was incubated at
0.6 WM, at 37‡C with 10 nM cathepsin L or 30 nM cathepsin K in
50 mM sodium acetate pH 5.5, 2 mM dithiothreitol (DTT), 5 mM
EDTA; 50 nM cathepsin B in 50 mM sodium acetate pH 6.0, 2 mM
DTT, 5 mM EDTA; 25 nM cathepsin D in 50 mM sodium citrate pH
3.3; 25 nM MMP in 50 mM Tris^HCl pH 7.5, 10 mM CaCl2, 150 mM
NaCl, 0.05% Brij-35, 50 WM ZnSO4 ; 25 nM elastase in 50 mM so-
dium acetate pH 6.0. All incubations were at 37‡C. They were stopped
at the indicated times with 0.25 WM E64c for cathepsins L, B and K;
0.25 WM pepstatin A for cathepsin D; 0.25 WM BB94 for MMPs.
Aliquots were then subjected to SDS^PAGE in 12% acrylamide
(Pharmacia), under reducing conditions. Gels were stained with silver
nitrate, or subjected to Western blot, using an anti-£ag M2 monoclo-
nal antibody (Sigma).
2.3. N-terminal amino acid sequencing
The NC1 cleavage products were separated in 12% acrylamide gels
(Pharmacia), and electroblotted onto PVDF membranes (Applied
Biosystems). Membranes were stained with Coomassie brilliant blue
R-250. The bands of interest were excized, and the N-terminal amino
acid sequence determined by Edman degradation on a Procise se-
quencer (Applied Biosystems).
2.4. Incubations of human endostatin (hES)
Recombinant hES (peptide starting at position H130SHRF) [17],
was incubated with proteinases in the same bu¡ers as NC1. At the
indicated times, aliquots of the mixtures were taken and analyzed by
SDS^PAGE, as described above. In order to determine whether MMP
activity was lost during the incubations, the level of activity was mea-
sured before and after the incubations, using the synthetic substrate
Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 [28].
3. Results
3.1. Generation of hES proteins by a variety of proteinases
We incubated recombinant hNC1 with a wide range of pro-
teinases at known molar concentrations of active enzyme,
analyzed the reaction mixtures by SDS^PAGE (Fig. 1) and
determined the N-terminal amino acid sequence of the bands
of interest (Fig. 2). These proteinases included representatives
of several classes of proteinases, i.e. cathepsins L, B and K
from the cysteine proteinase family; cathepsin D from the
aspartic proteinase family; MMP-2, MMP-3, MMP-9,
MMP-12, MMP-13, MMP-14 and MMP-20 from the MMP
family, and pancreatic elastase from the serine proteinase fam-
ily.
As shown previously [21], cathepsin L processed hNC1 to a
25 kDa fragment with the N-terminus L119RPARPTSPPAHS,
which is 11 residues longer than the cathepsin L-generated
murine fragment de¢ned as endostatin. In this paper, we
will refer to this cathepsin L-generated human peptide as
‘L-h-endostatin’. In our assays, cathepsin L completely pro-
cessed NC1 to L-h-endostatin within 15 min. Cathepsin B also
generated the same L-h-endostatin fragment (Figs. 1 and 2),
but complete processing required about 1 h, when using an
enzyme concentration ¢ve times higher than in cathepsin L
assays. Cathepsin K, also generated L-h-endostatin, but com-
plete processing required about 5 h incubation, when using an
enzyme concentration three times higher than in cathepsin L
assays. Cathepsin K generated additional proteolytic frag-
ments. The major products below 25 kDa corresponded to
N-terminal fragments of NC1, as revealed by Western blot
using an anti-£ag M2 antibody, and by N-terminal sequencing
(data not shown).
All seven MMPs tested processed hNC1, and generated a
Fig. 1. Processing of recombinant hNC1 by proteinases. hNC1 was
incubated for the indicated times with various proteinases as ex-
plained in Section 2, and the reaction mixtures were analyzed by
SDS^PAGE. Migration distances of molecular mass markers and
NC1 are indicated on the left. Empty arrowheads on the right indi-
cate the proteolytic products subjected to amino acid sequencing.
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very similar pattern of fragments in SDS^PAGE. The major
accumulating product was a peptide of about 25 kDa, as well
as a slightly longer peptide in the case of MMP-9 (Fig. 1). The
latter two peptides proved to have an N-terminal extension of
5 and 12 residues, respectively, when compared to L-h-endo-
statin (Fig. 2). Peptides smaller than 25 kDa corresponded to
N-terminal fragments of NC1 as determined by Western blot
and N-terminal sequencing (data not shown). Signi¢cant dif-
ferences in the e⁄ciency of hNC1 cleavage were observed
amongst these seven MMPs. MMP-3, MMP-9, MMP-12,
MMP-13 and MMP-20 completed the reaction in about 5 h
(Fig. 1). In contrast, under the same experimental conditions,
MMP-2 and MMP-14 led to only little accumulation of endo-
statin-like fragments after 20 h incubation.
The pancreatic serine elastase cleaved hNC1 at one position
closer to its C-terminal, compared to L-h-endostatin (Fig. 2).
The reaction was completed within 15 min like in cathepsin L
assays, but using an elastase concentration twice as high as
cathepsin L.
The aspartic proteinase cathepsin D cleaved NC1 very
quickly, but only transient products larger than 34 kDa
were detected (Fig. 1).
3.2. Proteolytic degradation of endostatin
Fig. 1 shows that cathepsins L and B not only generated L-
h-endostatin from hNC1, but also degraded it quickly, and
after 3 h incubation, only small amounts of L-h-endostatin
were left. In contrast, cathepsin K was much slower in degrad-
ing the generated L-h-endostatin, which remained in the re-
action media for longer than 5 h.
MMP-3, -9, -12, -13 and -20 produced endostatin fragments
that accumulated after 20 h incubation, suggesting that
MMPs cannot degrade them. Elastase was able to remove
the endostatin peptide that it had generated, but it was de-
tected only in the 20 h assays. In addition, the e⁄ciency of
these proteinases in endostatin degradation was directly inves-
tigated by incubating them with hES [17] (Fig. 3). Again a
wide range of e⁄ciencies was observed, supporting the data of
Fig. 1. Cathepsins L and D were the most e⁄cient and re-
moved completely endostatin in 1^2 h. Cathepsins B and K
also degraded endostatin, but incubations over 5^10 h were
Fig. 2. Identi¢cation of proteolytic cleavage sites in the NC1 do-
main of human collagen XVIII. The amino acid sequence of hNC1
is from [31]. Substitutions in mouse NC1 are indicated below in
italics [11]. The ¢gure shows the N-terminal sequence of endostatin-
like fragments detected in human plasma (full triangle) and in
mouse (empty triangle) [8,9], as well as the cleavage sites for cathep-
sin L (L), cathepsin K (K), cathepsin B (B), MMP-9 (M) and pan-
creatic elastase (E) reported in this work. The thick arrow indicates
the N-terminus of the originally described mouse endostatin.
Fig. 3. Incubation of recombinant hES with proteinases. 2.5 WM
hES was incubated with 25 nM MMP for 22 h, or with 25 nM
cathepsins L, K, D and pancreatic elastase or 50 nM cathepsin B
for the indicated times. Control samples containing only hES were
run in parallel. Molecular mass markers are indicated on the left.
Fig. 4. Mode of action of proteinases in the control of angiogenesis.
The overall e¡ect of a proteinase in angiogenesis is determined by
its relative e⁄ciency to promote angiogenesis and to increase the
concentration of antiangiogenic factors (e.g. endostatin, angiostatin).
The latter depends on its relative e⁄ciency to generate and degrade
the antiangiogenic factor.
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required to complete the reaction. The MMPs appeared to-
tally ine⁄cient in degrading endostatin, even upon 22 h in-
cubation. The pancreatic elastase was not e⁄cient, and incu-
bations over 22 h were required to detect a decrease in
endostatin levels.
4. Discussion
The present study shows that many di¡erent types of pro-
teinases, all tested at similar concentrations of active enzyme,
cleave human collagen XVIII’s NC1 within a region of about
15 residues, thereby releasing endostatin proteins. This ¢nding
has several interesting implications.
First, the previous studies showing that cathepsin L and
elastase generate precisely the fragment initially de¢ned as
endostatin, concerned cleavage of mouse NC1 [21,22]. In con-
trast, the present data are the ¢rst identifying multiple pro-
teinases processing hNC1. We show that cathepsin L and
pancreatic elastase generate endostatin proteins that are 11
and 10 residues longer than mouse endostatin, respectively.
Cathepsins B and K cleave hNC1 at the same site as cathepsin
L. The respective cleavage sites into mouse and hNC1 are as
expected from the non-conserved amino acid sequence of
mouse and hNC1, and from the preference of these protein-
ases for substrates with large hydrophobic or non-polar resi-
dues at P2 position [29], i.e. Val for YVH s LRP in hNC1,
and Leu in SLA s HTH in mNC1. The sequence correspond-
ing to the latter in hNC1 is PPA HSH, where P2 is Pro, a
small non-polar amino acid, and accordingly, cleavage does
not occur.
Second, it is of interest that endostatin fragments of similar
length are present in human tissues and plasma ([8,9] ; Fig. 2).
The cleavages found in our test tube experiments are thus
relevant to those occurring under physiological situations.
They further support conclusions from a structural study,
that the central hinge region of NC1 is especially sensitive
to proteolysis [8]. It should be emphasized that the collagen
XVIII fragment initially de¢ned as endostatin has neither
been detected in humans nor generated in our test tube assays.
The existence of a unique biologically relevant endostatin
molecule corresponding strictly to the initial de¢nition may
thus be questioned. Consistent with this view is the observa-
tion that endostatin-like fragments similar to those described
in this study inhibit endothelial cell migration. The removal of
¢ve residues or the addition of a £ag-tag at either the N-
terminal or C-terminal ends of recombinant hES does not
a¡ect its activity in endothelial cell migration assays [17].
However, the molecular mode of action of endostatin or en-
dostatin-like molecules is unknown, and it has not yet been
shown exactly what portion of the endostatin peptide is re-
quired for biological activity. The latter is di⁄cult to assess
experimentally, as it is not possible to control the molecular
transformations the peptide may undergo after its addition to
culture media, or in in vivo situations.
Third, although 11 of the 12 proteinases tested generated
endostatin-like fragments, they do this with di¡erent e⁄cien-
cies. Cathepsin L and elastase are clearly the most e⁄cient.
Cathepsin B, MMP-9, MMP-3, MMP-12, MMP-13, and
MMP-20 appear 4 to 20 times less active, while MMP-14
and MMP-2 appear at least 100 times less active compared
to cathepsin L and elastase. The e⁄ciency of MMP-14 and
MMP-2 may, however, be signi¢cantly higher in tissues, since
they may reach high local concentrations on the cell plasma
membrane. Therefore, even lower activities in test tube assays
may be relevant and should not be overlooked.
Finally, our data point to the fact that the actual concen-
tration of endostatin-containing fragments in a tissue will not
depend only on the e⁄ciency of proteinases to generate them,
but also on their ability to destroy them. Cathepsins L and B
generate endostatin fast, but also degrade it e⁄ciently. It is
therefore expected that these cathepsins will generate high
levels of endostatin only if the endostatin can di¡use away
from the more acidic environment in which it is generated
[21]. MMPs generate endostatin-like fragments quite e⁄-
ciently, but do not degrade them.
These observations should be interpreted in the general
context of angiogenesis. A wide variety of proteinases appear
necessary for angiogenesis. They are involved in endothelial
cell proliferation, migration, invasion through connective tis-
sue barriers, and release of growth factors from the extracel-
lular matrix [1^5]. Collagen XVIII is a major protein of the
matrix surrounding endothelial cells, and is therefore directly
available to proteinases for the generation of endostatin pro-
teins controlling angiogenesis in a feed-back mechanism [21].
The overall e¡ect of a proteinase will thus depend on its rel-
ative e⁄ciency in promoting angiogenesis, and in allowing
accumulation of endostatin-like fragments (Fig. 4). This
mechanism should be relevant to many situations where an-
giogenesis is occurring, since basement membrane collagen
XVIII is widely distributed, and proteolytic release of endo-
statin is not restricted by a requirement for speci¢c protein-
ases. This mechanism also applies to the release of angiostatin
from the widely distributed plasminogen [30].
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